Skip to main content
SpringerLink
Log in

Mammakarzinom: Chemotherapie trotz dualer HER2-Blockade wichtig

  • Gynäkoonkologie
  • Literatur kompakt
  • Published:
Im Focus Onkologie Aims and scope

Die Chemotherapie bleibt weiterhin ein wichtiger Bestandteil der Behandlung von Patientinnen mit HER2-positivem, Hormonrezeptor(HR)-negativem Mammakarzinom, selbst wenn sie eine duale HER2-Blockade erhalten.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Nitz UA et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab 6 weekly paclitaxel. Ann Oncol. 2017;28(11):2768–72.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Judith Neumaier

Authors
  1. Judith Neumaier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Neumaier, J. Mammakarzinom: Chemotherapie trotz dualer HER2-Blockade wichtig. Im Focus Onkologie 21, 41–42 (2018). https://doi.org/10.1007/s15015-018-3895-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-3895-0

Search

Navigation